Patents Examined by Brian J. Gangle
  • Patent number: 10206992
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 19, 2019
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 10087243
    Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: October 2, 2018
    Assignees: New York University, Janssen Biotech, Inc.
    Inventors: Victor J. Torres, Randall J. Brezski, Anthony Lynch, William Strohl, Brian Whitaker, Mark Chiu, Peter T. Buckley, Keri Dorn, Michelle Kinder
  • Patent number: 10081677
    Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: September 25, 2018
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Patent number: 10066024
    Abstract: A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with: (i) a synthetic zinc mimicry compound having structural and electronic properties similar to a catalytic domain of the metalloenzyme; and (ii) the metalloenzyme, Antibodies generated by this method are also disclosed as well as uses thereof.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 4, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Netta Sela-Paswell, Moran Grossman
  • Patent number: 10023617
    Abstract: Methods and systems for efficient and cost-effective production of lantibiotics. The methods and systems are capable of producing lantibiotics having high purity suitable for pharmaceutical use.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 17, 2018
    Assignee: ImmuCell Corporation
    Inventors: Joseph H. Crabb, John W. Zinckgraf, Hanna Froebe
  • Patent number: 10022452
    Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 17, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
  • Patent number: 9945855
    Abstract: A method for using a single sample suspected of containing a microorganism for both a local rapid test immunoassay and a remote laboratory test. The sample is collected from a patient at a physician's office or from the environment to be tested. The sample is collected using a swab or other implement, combined with a rapid test processing reagent and a portion of the processed sample is used for the local rapid test. The rapid test processing reagent typically consists of a buffer, a salt, and a detergent and is compatible with the local rapid test immunoassay. Only a portion of the processed sample is used for the local rapid test, leaving a remaining portion of the processed sample to be used in a remote laboratory assay. At least some of the remaining portion of the processed sample is combined with a stabilization agent that preserves at least the nucleic acid in the processed sample for the remote laboratory assay.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: April 17, 2018
    Assignee: Becton, Dickinson and Company
    Inventors: John J. Carrino, James Fan
  • Patent number: 9873739
    Abstract: The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced proteolysis of a Transforming Growth Factor-beta (TGF?) superfamily protein.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: January 23, 2018
    Assignee: Ikaika Therapeutics, LLC
    Inventors: Elizabeth McNally, Ahlke Heydemann, Ermelinda Ceco
  • Patent number: 9872895
    Abstract: The disclosure relates to antiviral therapeutic methods and related compositions. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection by administering a pharmaceutical composition comprising a TLR5 ligand, such as a flagellin, to a subject in need thereof.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: January 23, 2018
    Assignee: Emory University
    Inventors: Andrew T. Gewirtz, Benyue Zhang
  • Patent number: 9855324
    Abstract: The invention provides an immunogenic composition comprising one or more GBS conjugates and one or more antigens selected from: a) cellular or acellular pertussis antigen, b) a tetanus toxoid, c) a diphtheria toxoid and d) an inactivated polio virus antigen, wherein each GBS conjugate is a group B streptococcus capsular saccharide conjugated to a carrier protein. The invention also provides a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 2, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Mario Contorni, Guido Grandi, Domenico Maione, Immaculada Margarit Y Ros
  • Patent number: 9845359
    Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: December 19, 2017
    Assignee: Genentech, Inc.
    Inventors: Junichiro Sonoda, Yan Wu
  • Patent number: 9833483
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 5, 2017
    Assignee: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Patent number: 9822176
    Abstract: Novel anti-interleukin 3 (IL-3) antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN (SEQ ID NO: 2). The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: November 21, 2017
    Assignee: UNIVERSITÄTSKLINIKUM REGENSBURG
    Inventors: Matthias Mack, Hilke Brühl, Kerstin Renner
  • Patent number: 9822170
    Abstract: Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 21, 2017
    Assignee: Alethia Biotherapeutics Inc.
    Inventors: Gilles Bernard Tremblay, Elisabeth Viau, Mario Filion
  • Patent number: 9821028
    Abstract: Disclosed herein are methods of controlling parasitic worms in herbivorous mammals and other species by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an interleukin-10 peptide. In the case of herbivorous mammals such as cattle, for example, administration of the anti-IL-10 antibodies increases weight gain and increases feed efficiency in the animals.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: November 21, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark Eric Cook, Daniel Meilahn Schaefer, Mitchell Raymond Schaefer, Jordan Marshall Sand, Larry Smith
  • Patent number: 9821029
    Abstract: Described herein are methods of reducing Salmonella in the intestines of poultry in need thereof by administering to a poultry bird an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide. Administering may be performed within 1 to 4 weeks of harvest of the poultry in order to reduce Salmonella transmission to human consumers. Also included herein are finishing feeds that include an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: November 21, 2017
    Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Mark Eric Cook, Jordan Marshall Sand, Mike H. Kogut, Christina L. Swaggerty
  • Patent number: 9822153
    Abstract: The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of a Plasmodium parasite capable of infecting a mammalian host. The lentiviral vector particles are used in order to elicit an immunological response against malaria parasites.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 21, 2017
    Assignee: INSTITUT PASTEUR
    Inventors: Pierre Charneau, Frederic Philippe Coutant
  • Patent number: 9822406
    Abstract: The testing for the Lyme disease pathogen, (Borrelia bergdorferi (Bb) and all other Lyme Borrelia), is notoriously difficult. Bb is not by nature a blood loving bacteria, and prefers the climate of avascular tissues such as cartilage. The Borrelia Provocation Procedure disclosed herein proposes to uniquely lure the Lyme Borrelia spirochetes into the blood through a simple procedure of sub-dermal injection of benign tick saliva and co-factors. Lyme Borrelia can then be tested accurately after the provocation injection (BPP), utilizing any Lyme Borrelia detection test ideally as a specific PCR (polymerase chain reaction) test for the most accurate results as there will be abundantly available DNA present in the blood if there is an existing infection. Treatment is more effective after provocation as well, due to the same action of the Bb. The provocation protocol taught herein makes accurate, non-invasive, active direct Lyme infection testing possible, and creates a platform for an effective treatment as well.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 21, 2017
    Assignee: TITAN COLLABORATIVE KITHE, LLC
    Inventor: Dominique Desrochers
  • Patent number: 9814758
    Abstract: The invention relates to fragments of the Death-Domain Associated protein (DAXX protein) and of the Fas-Associated Death Domain protein (FADD protein) that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: November 14, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE MONTPELLIER 2-SCIENCES ET TECHNIQUE, UNIVERSITE DE MONTPELLIER 1
    Inventors: Stéphanie Barrere, Joël Nargeot, Bernard Lebleu, Prisca Boisguerin, Christophe Piot
  • Patent number: 9808519
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: November 7, 2017
    Assignee: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue